ARGX 590.06 (+1.1%)
US04016X1019BiotechnologyBiotechnology

Argenx (ARGX) Stock Highlights

590.06 | +1.1%
2025-04-03 20:58:42
argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.

Statistics

Range Today
585 595.46
Volume Today 631.97K
Range 1 Year
352.77 678.21
Volume 1 Year 73.63M
Range 3 Year
267.35 678.21
Volume 3 Year 218.73M
Range 10 Year
17.33 678.21
Volume 10 Year 428.44M

Highlights

Market Capitalization 35.93B (large)
Floating Shares 60.99M
Current Price 590.06
Price To Earnings 46.71
Price To Revenue 14.5
Price To Book 6.51
Earnings Per Share 12.76
Payout Ratio 0%

Performance

Latest +1.1%
1 Month -7.86%
3 Months -5.56%
6 Months +7.37%
1 Year +49.35%
3 Years +78.88%
5 Years +349.71%
10 Years +3196.42%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.